Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed ...
Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on January 14th, the Representative disclosed that they had sold between ...
The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue ...
Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.
The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations ...
Zacks.com on MSN6d
LLY Falls Around 14% in 3 Months: How to Play the StockEli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...
FOIA requests to the federal government often are signals. They can be an important early warning of bad publicity, litigation to come, or uncertainties to be hedged and gamed out. When the flow of ...
Recent market research reveals that glucagon-like peptide-1 (GLP-1) injections are set to dominate the obesity treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback